Company page

Transgene Sa

Transgene SA is a public company listed on the French market under the ticker TNG, with a market capitalization of approximately €238.89 million. The company focuses on developing innovative immunotherapies for cancer treatment. Transgene is committed to advancing its pipeline of therapeutic candidates to address unmet medical needs in oncology.